Bipolar Disorder – Landscape & Forecast – Disease Landscape & Forecast

Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the mainstay therapies used to treat BPD; their long-standing stronghold as patient-share leaders contribute to the challenges that branded therapies face entering this crowded therapy market. Nevertheless, current treatments have multiple shortcomings; thus, novel therapies with the potential to capitalize on the remaining opportunities in BPD treatment could drive growth of this market. In addition to newer-to-market antipsychotics (e.g., Alkermes’s Lybalvi, Intra-Cellular Therapies’ Caplyta), a handful of emerging therapies from a variety of drug classes are in late-phase development (e.g., Vanda Pharmaceuticals’ iloperidone, NeuroRx’s NRX-101, Sunovion / Sumitomo Dainippon / Otsuka’s SEP-4199), and still more are in early development (e.g., psychedelics). If successful, they could offer new treatment options for BPD.

Questions answered

  • What is the current size of the BPD therapy market in the G7 countries? What key events will influence the market over the next decade?
  • What is the epidemiology of BPD in the G7 countries? What percentage of prevalent patients are diagnosed and drug-treated?
  • What factors drive and constrain the use of branded atypical antipsychotics in the treatment of BPD? Which branded therapy is expected to experience the most commercial success during the forecast period?
  • What are the greatest areas of unmet need in the treatment of BPD, and how are emerging therapies expected to address these unmet needs?

Geographies: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this research

Epidemiology: Lifetime prevalence, diagnosed prevalence, and drug-treated prevalence of BPD by country

Forecast: 10-year, annualized, drug-level sales and patient share of key BPD therapies through 2032, segmented by brands / generics

Emerging therapies: Preregistration / Phase 3: 5 drugs; coverage of select early-phase products

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports